Zydus Lifesciences Limited has announced the closure of an inspection conducted by the US Food and Drug Administration (USFDA) at its LiqMeds facility in the UK. The inspection, which took place from November 9 to November 13, 2026, concluded with 4 observations. The company has stated it will work closely with the USFDA to address these observations expeditiously.
USFDA Inspection Concluded at Zydus LiqMeds, UK
Zydus Lifesciences Limited has informed stakeholders about the completion of an inspection by the US Food and Drug Administration (USFDA) at its facility, LiqMeds, located in the UK. The inspection was conducted over a period of five days, from November 9, 2026, to November 13, 2026.
Inspection Outcome and Next Steps
The inspection concluded with a total of 4 observations. Zydus Lifesciences has assured that it is committed to addressing these observations promptly and comprehensively. The company will be working closely with the USFDA to ensure the expeditious resolution of all raised points. This disclosure is made in accordance with regulatory requirements, providing transparency to investors and the market.
The company’s management expressed confidence in its ability to meet regulatory standards and is focused on maintaining compliance across all its global manufacturing sites.
Source: BSE
